The patent for the drug is held by Pharmacyclics for three to four more years in India. Pharmacyclics was globally acquired by US giant AbbVie in 2015 in a massive USD21 billion deal. Natco's latest move is consistent with its earlier launches and challenging the patents held on anti-cancer drugs by multinational drug companies.from Industry-Economic Times
Read The Rest:economictimes...
